Efficacy and Safety of Favipiravir in Covid-19 Patients in Indonesia
Status:
Recruiting
Trial end date:
2021-12-30
Target enrollment:
Participant gender:
Summary
The benefit of the research is to provide information regarding the efficacy and safety of
Favipiravir plus the Standard of Care (SoC) for mild-moderate COVID-19 patients to be a
reference for policy recommendations regarding the use of Favipiravir as an antiviral drug
for the treatment of Covid-19.
Phase:
Phase 3
Details
Lead Sponsor:
Ina-Respond
Collaborator:
Center for Research and Development of Health Resources and Services, National Institute of Health Research and Development (NIHRD), Indonesia